We are live on ! Find out more
CNTB

Connect Biopharma Holdings
CNTB

14 hedge funds and large institutions have $8.22M invested in Connect Biopharma Holdings in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.52% less ownership

Funds ownership: 18.82% → 18.3% (-0.52%)

13% less funds holding

Funds holding: 16 → 14 (-2)

30% less capital invested

Capital invested by funds: $11.7M → $8.22M (-$3.46M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.37K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$200
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$42

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$244K
2
BFM
Boothbay Fund Management
New York
-$30.4K
3
JP Morgan Chase
JP Morgan Chase
New York
-$22.6K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11.6K
5
Two Sigma Investments
Two Sigma Investments
New York
-$5.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$5.73M – – –
BlackRock
2
BlackRock
New York
$922K – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$532K – – –
UOC
4
UBS O'Connor
Illinois
$469K – – –
KCM
5
Kynam Capital Management
New Jersey
$434K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$79K +$1.37K +1,500 +2%
JP Morgan Chase
7
JP Morgan Chase
New York
$18.2K -$22.6K -24,840 -51%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$14.8K – – –
Two Sigma Investments
9
Two Sigma Investments
New York
$14.1K -$5.8K -6,367 -27%
RhumbLine Advisers
10
RhumbLine Advisers
Massachusetts
$12.8K +$6K +6,585 +66%
Qube Research & Technologies (QRT)
11
Qube Research & Technologies (QRT)
United Kingdom
$36 +$42 +46 New
Fidelity Investments
12
Fidelity Investments
Massachusetts
$18 – – –
Morgan Stanley
13
Morgan Stanley
New York
$1 – – –
IC
14
Ikarian Capital
Texas
– -$244K -219,501 Closed
BFM
15
Boothbay Fund Management
New York
– -$30.4K -26,867 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$11.6K -10,470 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– +$200 +220 +629%

CNTB Hedge Fund Activity: Q3 2023 in Review

14 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q3 2023, worth a combined $8.22M — down 30% from $11.7M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CNTB and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was RhumbLine Advisers, adding an estimated $6K. The largest seller was Ikarian Capital, exiting entirely with an estimated $244K sold.

  • 14 institutional investors held Connect Biopharma Holdings (CNTB) as of Q3 2023, down from 16 in Q2 2023.
  • Funds reported $8.22M of Connect Biopharma Holdings stock for Q3 2023, down 30% quarter-over-quarter.
  • 1 fund opened new Connect Biopharma Holdings positions in Q3 2023 and 3 closed out, a net change of -2 holders.
  • The largest Connect Biopharma Holdings buyer in Q3 2023 was RhumbLine Advisers, an estimated $6K added.
  • The largest Connect Biopharma Holdings seller in Q3 2023 was Ikarian Capital, an estimated $244K sold.

Based on aggregated 13F filings for Q3 2023.